According to a new report by Polaris Market Research, the global Endobronchial Valves Market was valued at USD 190.64 Million in 2025 and is projected to reach USD 321.53 Million by 2034, expanding at a CAGR of 6.0% over the forecast period. Growth is underpinned by rising chronic obstructive pulmonary disease (COPD) prevalence, expanding bronchoscopic lung volume reduction adoption, and accelerating minimally invasive pulmonology procedures across key end-use industries.

What Is Driving Endobronchial Valves Market Growth?

Demand is climbing as the rising global prevalence of COPD and other lung-related disorders converges with continued technological advancement in bronchoscopic device design. Manufacturers and end users are prioritizing minimally invasive treatment adoption, pushing adoption across hospitals and pulmonology centers. Polaris analysts note that guideline recognition of EBV-based bronchoscopic lung volume reduction as the highest-evidence-rated therapy for severe emphysema positions the segment for sustained growth through 2034, with the hospitals segment emerging as the largest revenue contributor and the clinical research center segment posting the fastest incremental gains.

Key Trends Shaping the Endobronchial Valves Industry

Guideline-Endorsed Therapy with High Evidence Rating

EBV-based bronchoscopic lung volume reduction is now guideline therapy for severe emphysema with severe hyperinflation and no relevant collateral ventilation, carrying the highest evidence rating among bronchoscopic interventions, reinforcing the competitive landscape of clinically validated treatment options.

Broader Application to Homogeneous Emphysema and Cardiac Benefits

New data show meaningful benefits in patients with severe homogeneous emphysema, not only heterogeneous cases, and suggest that reducing hyperinflation via endobronchial valves can improve cardiac function by relieving thoracic pressure — widening the addressable patient pool.

Consensus-Based Patient Selection and Real-World Outcomes

International expert consensus statements now provide detailed guidance on patient selection and target-lobe choice, while real-world registries show sustained lung-function benefits up to two years post-procedure, shaping a more favorable market outlook for device adoption.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/endobronchial-valves-market 

Market Segmentation: Breaking Down the Endobronchial Valves Market

Polaris segments the Endobronchial Valves Market by product type and end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product Type

Umbrella-shaped valves held a leading share of the market in 2025, on the strength of their ability to improve natural airflow around the valve, exemplified by the FDA-approved Spiration valve system. Duckbill-shaped valves is projected to expand at the fastest rate through 2034 as rising adoption of FDA-approved minimally invasive devices such as the Zephyr valve.

By End User

Hospitals remains the dominant segment, driven by the concentration of pulmonologist-led insertion procedures within hospital settings amid rising COPD case volumes. Clinical research centers is gaining share as a rapid increase in COPD-related clinical trials evaluating endobronchial valve efficacy, signaling where near-term demand — and search intent around "endobronchial valves by end user" — is shifting.

Regional Outlook: Where Is the Endobronchial Valves Growing Fastest?

North America led the market in 2025 on the back of the high burden of COPD, with roughly 16 million people affected in the United States alone, and strong FDA-approved device availability, while Asia Pacific is expected to post the fastest CAGR through 2034, driven by a growing elderly population and rising incidence of respiratory conditions including occupational lung disease and air-pollution-linked illness. Within North America, the United States remains the largest single market; within Asia Pacific, China is the primary growth engine. Europe rounds out the top three, supported by expanding reimbursement pathways and growing clinical trial activity across major pulmonology centers.

Competitive Landscape: Leading Endobronchial Valves Companies

Key players profiled in the report include Boston Scientific Corporation, Olympus Corporation, Pulmonx Corporation, Spiration Inc., and Broncus Medical Inc., who are focusing on product innovation and clinical partnerships to strengthen market position across the segments outlined above. Recent moves include an ATS Journal study published in May 2022 evaluated bronchoscopic lung volume reduction using endobronchial valves for decreasing hyperinflation in severe emphysema patients, and ongoing device refinements from Pulmonx and Olympus continue to expand FDA- and CE-marked indications for valve placement.

Why It Matters for Buyers Evaluating endobronchial valve suppliers and pricing

For stakeholders researching endobronchial valve suppliers and pricing, this report benchmarks market share, segment-level pricing, and forecast data — by segment and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking the clinical research center segment as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

B2B Digital Payment Market

Organic Rankine Cycle Market

Actinic Keratosis Treatment Market

Kitchen Appliances Market

Acidity Regulators Market

Acidity Regulators Market

Laundry Detergent Market

Immunotherapy Drugs Market

U.S. Viral Vector And Plasmid DNA Manufacturing Market